treatment courses. Based on studies in our mouse model and human tissues, 3, 4 we hypothesized that targeting the interferon-g (IFN-g)/C-X-C motif chemokine ligand (CXCL) 10 axis could be an effective new treatment strategy for vitiligo. 5 Recent case reports revealed that Janus kinase inhibitors, which block IFN-g signaling, are effective at reversing vitiligo, 6, 7 supporting our hypothesis. Clinical trials to test new, targeted treatments for vitiligo are on the horizon.
When conducting clinical trials on vitiligo, monitoring disease activity will be critical for measuring the treatment response. A common misconception is that biomarkers of treatment response are unnecessary, since the skin can be observed clinically; however, even the earliest clinical changes in vitiligo take 2-3 months to become apparent because of the time required for melanocyte precursors to proliferate, migrate, differentiate, and produce pigment. Measurable responses require 6 months or more, and current outcome measures are largely subjective and insensitive to small changes. 8, 9 Thus, relying only on observable changes in skin pigmentation is problematic.
Recent studies reported that serum levels of IFNgeinduced chemokines are elevated in patients with active vitiligo 4, 10 and correlate with treatment responses. 10 Serum chemokine levels, while reflecting general trends of disease activity in large cohorts, are likely too variable to serve as sensitive and specific markers of disease activity in a single patient. Moreover, patients with other autoimmune diseases exhibit increased inflammatory markers in the serum as well, 11, 12 precluding their use as specific markers in vitiligo. Measuring markers directly in the skin could be a more sensitive and specific approach; however, conventional analysis of skin through immunohistochemistry is problematic because lesions have low numbers of infiltrating T cells that are difficult to detect and quantify, unlike more inflammatory diseases. Thus, a more efficient method to sample vitiligo lesional skin and reliably measure treatment responses is needed.
We adapted a minimally invasive, nonscarring skin biopsy technique [13] [14] [15] [16] [17] to reliably and accurately sample vitiligo lesions by inducing suction blisters, which contain interstitial skin fluid 18 that can be used for analysis. Lesional blister fluid revealed an infiltrate of CD8 1 T cells and CXCL9 protein that was both sensitive and specific for disease activity, in contrast to analysis of patient blood and serum. Suction blistering provides an opportunity to sample lesional skin in patients in a minimally invasive way, while yielding highly useful material to study markers of disease activity for translational studies and treatment responses in clinical trials.
METHODS

Study design
Subjects were recruited into 2 sequential groups for this study: the first to define markers of disease activity in vitiligo, and the second to independently validate these markers in a separate, nonoverlapping group of subjects (Table I and  Supplemental Table I [available at http://www.jaad.org]). Inclusion/exclusion criteria were as follows: subjects with a diagnosis of vitiligo by clinical exam performed by a dermatologist and off treatment for at least 6 weeks were included in screening and validation groups. Subjects with recent onset of new lesions and objective clinical signs of activity, specifically confettilike macules or trichrome lesions, were recruited to represent the active subgroup. Subjects with stable disease or no recent change in lesions and no objective clinical signs of disease activity (no confetti, trichrome, or inflammatory lesions and no Koebner phenomenon) were selected on the basis of patient self-reports. Those on treatment, with other inflammatory skin diseases or presenting with the segmental subtype of vitiligo, were excluded from the study. One subject was blistered repeatedly before and after starting treatment to define the treatment response.
Suction-blister skin biopsy and fluid aspiration was performed with internal review boarde approved protocols at the University of Massachusetts Medical School and all samples were de-identified before use in experiments. Active subjects with a 1-month history of new or spreading lesions were blistered at sites featuring confetti-like depigmentation or trichrome lesions. 19, 20 In subjects with stable disease, sites along the lesional edge consisting of normal and depigmented skin were selected for suction blistering. The nonlesional sites selected were normal-appearing, nondepigmented
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Suction blistering is a minimally invasive method to measure immune biomarkers directly in skin. skin when examined by Wood's lamp and at least 5 cm from the nearest depigmented macule.
Blister induction and processing
Suction blisters (1 cm in diameter) were induced on the skin by using the Negative Pressure Instrument Model NP-4 (Electronic Diversities, Finksburg, MD). The suction chambers were applied to the skin with 10-15 mm Hg of negative pressure and a constant temperature of 408C; blisters formed between 30-60 minutes after initiation of the procedure. After blister formation, the blister fluid was aspirated through the roof using a 1 mL insulin syringe (Fig 1) . Cells within the blister fluid were pelleted at 330 3 g for 10 minutes for cell staining and the supernatant was collected and frozen for future analysis by enzyme-linked immunosorbent assays (ELISA). Occasionally (9% of blisters), hemorrhage occurred in the blister: these blisters were excluded from analysis because their infiltrates were contaminated with cells from the peripheral blood and poorly reflected the cells constituting the interstitial fluid of the skin (data not shown).
ELISA and flow cytometry
In brief, the manufacturer's instructions were followed for ELISA and flow cytometry techniques. Further details are provided at http://www.jaad.org in the Supplemental Methods section.
Statistics
Statistical analyses were performed with GraphPad Prism software. Dual comparisons were made with the Wilcoxon's matched-pairs signed rank test for nonparametric data. Groups of $3 were analyzed by Kruskall-Wallis with Dunn post tests for nonparametric data. Multiplicity-adjusted P values from the Dunn post tests are reported as post test P values. Receiver operating characteristic (ROC) curve analysis was performed to determine the sensitivity and specificity of tests performed on blister samples. P values \.05 were considered significant.
RESULTS
T-cell infiltrates are elevated in active vitiligo lesions
As CD8 1 T cell recruitment to the skin is required for depigmentation, 4 we examined the T-cell number in the skin as a potential biomarker for active disease. Flow cytometry of blister fluid in the defining group initially revealed that active lesional sites had a larger infiltrate of CD8 1 T cells than nonlesional sites did; they also had more CD8 1 T cells than the skin of healthy individuals (Fig 2, A and Supplemental Fig 1; available at http://www.jaad. org). We and others reported that skin-infiltrating CD8 1 T cells express C-X-C motif chemokine receptor (CXCR) 3 when analyzed by immunohistochemistry. 4, 10, 21 Here we found that CD8 1 T cells uniformly express CXCR3 in the skin by flow cytometry (Fig 2, B ) supporting previous results.
We then sought to quantify the number of T cells in each blister. Lesional sites on average had a 2-fold increased number of CD8
1 T cells with a mean of 2727 cells compared with 1305 cells in nonlesional skin after normalization to CD45
1 cell count (analysis of variance, all sites, P = .0009; t test lesional to nonlesional, post test P = .0185; t test lesional to healthy, post test P = .0015). No appreciable differences were observed in infiltrates between nonlesional sites of active patients and healthy control skin (Fig 2, C ) . We also found that the total CD3
1 T-cell number is significantly higher in active lesional skin with an average difference of 1.4-fold (7651 lesional, 5491 J AM ACAD DERMATOL VOLUME 76, NUMBER 5 nonlesional, P = .0015). Although the CD4 1 T cell number in the skin was elevated in the defining group, comparisons did not reach statistical significance in the validation group or when the total data was compiled (Supplemental Fig 2; available at http://www.jaad.org). We then used a ROC analysis to test whether CD8 1 T-cell number could be used to predict disease activity and found it had a reasonable predictive value (Fig 2, D) : a threshold of 1175 normalized CD8
1 T cells achieved a sensitivity of 70% with specificity of 64%.
We next completed the same analyses in a second group of subjects to validate our observations and found similar results: lesional infiltrates contained significantly higher CD8
1 T cells than nonlesional sites did (post test P = .0494). This group also included 4 subjects with stable vitiligo, and the T-cell number in the skin (lesional and nonlesional) of these individuals were reduced in comparison with that in the lesional skin of persons with active vitiligo (post test P \ .0001 and post test P \ .0001, respectively) (Fig 2, E ) . ROC analysis of this group revealed that a threshold of 2766 normalized
CD8
1 T cells yields 83% sensitivity and 92% specificity (Fig 2, F ) .
Skin CXCL9 protein is a more sensitive and specific marker of disease activity than CXCL10
We previously reported that CXCL9 and CXCL10 RNA transcripts were elevated in lesional skin of vitiligo patients.
4 CXCR3 1 CD8 1 T cells use CXCL9, CXCL10, and CXCL11 to traffic towards sites of inflammation 22 and CXCL10 is functionally required for the progression and maintenance of vitiligo. 4 By ELISA, we found that CXCL9 was significantly elevated in lesional blister fluid compared with that in nonlesional skin and healthy controls and predicted disease activity better than CD8
1 T-cell numbers (Fig 3, A) . When we examined CXCL10 in the skin of patients with vitiligo, we discovered it was not significantly higher in the active lesional skin and did not have good predictive value for disease activity (Fig 3, B) . When we evaluated CXCL9 as a candidate biomarker in the second validation group, we detected an average 5.5-fold difference between active lesional sites and nonlesional skin (post test P = .0492). ROC analysis suggested that CXCL9 is a more sensitive and specific marker of disease activity than T-cell number, achieving a threshold value of 1177 pg/mL with 100% sensitivity and 93% specificity (Fig 3, C ) . We also evaluated CXCL10 in the skin of patients in the validation group and found similar results as the first group, although this time the level of CXCL10 was 3.5-fold higher in lesional skin compared with nonlesional skin (post test J AM ACAD DERMATOL VOLUME 76, NUMBER 5 P = .0243). Despite detecting elevated levels of CXCL10 in active disease, these differences did not significantly increase the predictive value of CXCL10 (Fig 3, D) . In initial subjects, CXCL11 and IFN-g were detected only at low levels, if at all, and levels of these chemokines in lesions were not elevated compared with that in nonlesional sites or healthy control skin, despite having elevated CXCL9 and CXCL10 ( Supplemental Fig 3; available at http://www.jaad.org). Thus, we did not measure these cytokines in the remaining subjects.
It was previously reported that serum CXCL9 and CXCL10 were significantly elevated in a large cohort of vitiligo patients compared with healthy controls and that upon intervention, the levels of CXCL10, but not CXCL9, significantly dropped. 10 However, we did not see a correlation between serum chemokines and disease activity in either cohort or in the total group when both cohorts were combined (Fig 4,  A-C ) , perhaps because of small sample size or selecting patients with active disease phenotypes. Serum levels of CXCL11 and IFN-g were either undetectable or not significantly different in sampled patients (Fig 4, D) .
Case study: CXCL9 protein is most responsive to multimodal treatment at an early time point
We followed one patient who was undergoing treatment for vitiligo with narrow band ultraviolet B phototherapy and alternating topical tacrolimus and clobetasol. We sampled the same locations where the patient exhibited confetti on the first visit and at each subsequent visit. After the first 4 months, the patient reported inconsistent use of treatment, and no treatment for the previous 4 weeks. At this time, her T-cell number remained largely unchanged from her initial visit, yet after an additional 4 months of consistent phototherapy and tacrolimus use, the CD8 1 T-cell number in her lesional tissue declined 2-fold. However, her nonlesional CD8
1 T-cell count also decreased, leading to no change in the T-cell count ratio between lesional to nonlesional tissue (Fig 5, A) . Interestingly, lesional CXCL9 was decreased at the second visit and undetectable at the third visit (Fig 5, B) . Serum CXCL9 was undetectable at the final visit as well (Fig 5, C ) . Lesional and serum CXCL10 were decreased at both visits (Fig 5, D  and E ) . 
DISCUSSION
We adapted a modified suction-blister protocol to sample lesional skin from vitiligo patients and address the need for markers of disease activity and early treatment response. Our testing of potential biomarkers was based on observations we made in our mouse model of vitiligo and in vitiligo patients. Thus, this work was hypothesis-directed rather than a screen of multiple unrelated parameters. While both CD8
1 T-cell number and CXCL9 in the blister fluid demonstrated good predictive value in identifying those with active disease, CXCL9 had better sensitivity and specificity, and CXCL10 correlated only weakly.
In contrast to previous studies, 4,10 we could not use serum chemokine levels to distinguish those with active disease from those with stable disease or even healthy controls. This might have resulted from the small number of subjects enrolled in this study compared with other studies or from the patient selection used for this study (requiring highly active confetti or trichrome patterns). Either way, it highlights the limitations of using serum markers to reliably measure disease activity in individual patients, and the advantage of skin-specific analyses.
Our results also indicate that blister fluid CD8 1 T-cell infiltration and CXCL9 protein are not induced by the blistering process itself because nonlesional sites showed minimal levels of both. CXCL10 was elevated in the nonlesional skin of some subjects, which could have been caused partially by the blister trauma and might explain why it is a less specific marker when using this method. Alternatively, CXCL9 protein might be more bioavailable in blister fluid and easier to detect by ELISA than CXCL10 on the basis of their different spatial and temporal expression in the skin, 23 binding affinities to structural elements, 24, 25 and oligomerization within tissues. 26 We previously reported that both CXCL9 and CXCL10 had functional roles in our mouse model of vitiligo; however, only CXCL10-deficient mice were protected from clinical disease. 4 Although both chemokines are expressed in active disease, they are produced by different cell types with different kinetics during vitiligo progression.
23
CXCL9 is expressed earliest in murine vitiligo lesions and might be a more specific marker of disease activity. 23 These markers might provide important information to support activities in clinical trials: 1) to help efficiently identify and enroll subjects with active IFN-gespecific inflammation; 2) to reveal early treatment responses and drug efficacy; and 3) to improve the sensitivity of current, subjective outcome measures. Future studies will further characterize these biomarkers and their sensitivity to change following treatment in a larger patient cohort, where subgroup analysis by disease variants or by subject demographics could provide additional clues for categorizing vitiligo. Future studies could assess the effects of sun exposure on these parameters; our data was gathered primarily in the colder months in the Northeast, where sun exposure is less intense. Finally, this modified suction-blister technique provides an unparalleled opportunity to sample lesions in patients with other inflammatory skin diseases to study the natural history of these diseases and their treatment responses.
We thank our patients for their generous contribution of tissues, and Celia Hartigan and staff of the Clinical Research Center at University of Massachusetts Medical School for assistance with study subject appointments. Flow cytometry equipment was maintained by the University of Massachusetts Medical School Flow Cytometry Core Facility.
SUPPLEMENTARY METHODS
Enzyme-linked immunosorbent assay (ELISA)
Human IFN-g, CXCL9, CXCL10 and CXCL11 Duoset ELISA kits (R&D Systems, Minneapolis, MN) were used to measure protein concentrations in blister fluid according to the manufacturer's instructions. Optical densities were measured at 450 nm using a PerkinElmer EnVision 2102 multilabel reader (PerkinElmer, Waltham, MA) and used to calculate concentrations using a 4-parameter logarithmic standard curve with free ELISA analysis software. Based on preliminary observations, we excluded samples from subjects with elevated CXCL9 and CXCL10 in the serum due to the potential for retrograde diffusion of the chemokine into skin fluid, confounding analysis.
Flow cytometry
All samples were blocked with Human TruStain FcX (BioLegend, San Diego, CA) and stained with LiveDead Blue (Invitrogen [Carlsbad, CA] 1:1000). The following antibodies were used at a 1:20 dilution: CD45 APC, CD4 PerCP (Tonbo Biosciences, San Diego, CA), CXCR3 PE, and CD8 PE-Cy7 (BioLegend). CD3 Pacific Blue (BioLegend) was used at a 1:200 dilution. Peripheral blood was used for comparison and to assist in gating. Samples were stained and then fixed and lysed using RBC Fixation/Lysis Buffer (Biolegend) per the manufacturer's instructions. Data were collected with an LSR II and analyzed with FlowJo software (FLowJo, LLC, Ashland, Oregon). 
